ERY 250MG
Code : ERY02
Price:
Contact
Manufacturer
Present/Packing Ery powder for oral suspension - Ery 250 mg x 24 sachets
Price
Features
Delivery
Share this product to others
Shopping
guide
Add to cart
Share this product to friends and family
ERY 250MG
Manufacturer:
Bouchara Recordati
Contents:
Erythromycin base 250 mg
Indications:
Listed in Dosage.
Contraindications:
Hypersensitivity; porphyria; hepatic impairment; pregnancy.
Special Precautions:
Increased
risk of cholestatic hepatitis when treatment is >10 days or in patients with
previous history of erythromycin usage. History of hepatic disorders;
arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid
estolate in liver impairment. Caution when using lactobionate in patients with
severe renal impairment. May aggravate muscle weakness in patients with
myasthenia gravis.
Dosage:
Adult:
PO Susceptible infections 1-2 g/day. Severe: Up to 4 g/day. Acne 250 mg/day.
Severe: Up to 500 mg twice daily. Prophylaxis against pneumococcal infections;
Prevention of streptococcal infections in patients w/ rheumatic fever or heart
disease 250 mg twice daily. IV Susceptible infections As lactobionate: 15-20
mg/kg/day. Severe: Up to 4 g/kg/day. Ophth Ophth infections As 0.5% oint: Apply
up to 6 times/day. Topical Acne As 2% gel/soln: Apply 1-2 times/day.
Class:
Macrolides
/ Acne Treatment Preparations / Eye Anti-Infectives & Antiseptics
Presentation/Packing:
Ery powder for oral suspension - Ery 250 mg x 24 sachets
Details:
MyPhuocPharmacy – (08) 62581003
Erythromycin base 250 mg
Adult:
PO Susceptible infections 1-2 g/day. Severe: Up to 4 g/day. Acne 250 mg/day.
Severe: Up to 500 mg twice daily. Prophylaxis against pneumococcal infections;
Prevention of streptococcal infections in patients w/ rheumatic fever or heart
disease 250 mg twice daily. IV Susceptible infections As lactobionate: 15-20
mg/kg/day. Severe: Up to 4 g/kg/day. Ophth Ophth infections As 0.5% oint: Apply
up to 6 times/day. Topical Acne As 2% gel/soln: Apply 1-2 times/day.
Updating
Increased
risk of cholestatic hepatitis when treatment is >10 days or in patients with
previous history of erythromycin usage. History of hepatic disorders;
arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid
estolate in liver impairment. Caution when using lactobionate in patients with
severe renal impairment. May aggravate muscle weakness in patients with
myasthenia gravis.